10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Neuropathy;Peripheral
Tanta UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Neuropathy;Peripheral cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin University of Rochester | Phase 4 | A |
LIDOCAINE University of Utah | Phase 4 | BBB |
Nabiximols VA Office of Research and Development | Phase 3 | BBB |
Eloxatin Tanta University | Phase 3 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Washington University School of Medicine | Phase 4 | BB |
View all 50 →
Same molecule, other indications
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →